Imfinzi (durvalumab) FDA approval for muscle-invasive bladder cancer: Nov 13, 2026
Page updated ·next FDA decision on the calendar·Data as of Nov 21, 2026 10:10 PM ET
✓ APPROVED
Imfinzi (durvalumab) was approved by the FDA on November 13, 2026 for adults with muscle-invasive bladder cancer ineligible for or refusing cisplatin-based chemotherapy, with enfortumab vedotin-ejfv before cystectomy, then alone after it.
This page was first committed to pdufa.bio's public repository on Nov 20, 2026, 4:09 AM ET (public commit 2b423a8). Dates on this page are the FDA's and the sponsor's; this line is ours.
Run-up into the decision (T-120 → T+4)
Daily close, T-120 (5/26/26) through T+4. Run-up high $195.15 on 7/2/26, low $155.62 on 8/4/26 (T-120 to T-1). FDA decision 11/13/26. Historical price action, not a forecast.
Key facts
FDA decision date2026-11-13
OutcomeApproved
Drug / candidateImfinzi (durvalumab)
IndicationAdults with muscle-invasive bladder cancer ineligible for or refusing cisplatin-based chemotherapy, with enfortumab vedotin-ejfv before cystectomy, then alone after it
CompanyAstraZeneca
Market-cap tierLarge
120-day run-up (T-120→T-1)-1.4%
Decision-day move+0.0%
Move measured on2026-11-13 close, against the 2026-11-12 close
Cohort decision-day move (history)1.0% median (n=647)
Drugs@FDA records BLA 761069 supplement 59 (efficacy) for Imfinzi as approved on November 13, 2026 (Drugs@FDA). AstraZeneca announced that evening that Imfinzi in combination with enfortumab vedotin-ejfv as neoadjuvant treatment, followed by Imfinzi monotherapy as adjuvant treatment after radical cystectomy, was approved for adults with muscle-invasive bladder cancer who are ineligible for or have refused cisplatin-based chemotherapy (AstraZeneca, November 13, 2026). We hold no publicly disclosed PDUFA goal date for this supplement, so no early or late margin is given.
Run-up figures are the stock's own daily closing path over the 120 trading days before the decision, from our price history. Cohort move is the historical median absolute decision-day move for this market-cap tier. History, not a prediction.
FDA record of the action: the FDA approved on November 13, 2026, per BLA 761069 SUPPL-59 (Drugs@FDA). The sponsor announced it the same day. Action dates on pdufa.bio come from the FDA's own record, not the press release. Every FDA action we hold, by FDA date: FDA approval letters.
Specialist biotech funds holding AZN, 13F for the quarter ended September 30, 2026
13F reports list long positions in common stock at quarter end, are due 45 days later, and show no short positions or later trades. Notes, warrants and other instruments are not counted as shares.
Questions
Was Imfinzi (durvalumab) approved by the FDA?
Yes. The FDA approved the application for Imfinzi (durvalumab) on November 13, 2026, per the FDA's own record. The primary source is linked on this page.
Which company is behind Imfinzi (durvalumab)?
Imfinzi (durvalumab) is an AstraZeneca (AZN) program. The FDA decision came on November 13, 2026; the FDA's own record of the decision is linked on this page.
How did AZN stock react to the FDA decision?
AZN moved +0.0%, measured as the 2026-11-13 close against the 2026-11-12 close. It is one trading day's move, so it can include news other than the decision. Historical measurement, not a prediction, and not investment advice.
What did the FDA approve for Imfinzi on November 13, 2026?
Per Drugs@FDA and AstraZeneca, Imfinzi (durvalumab) with enfortumab vedotin-ejfv before radical cystectomy, followed by Imfinzi alone after surgery, for adults with muscle-invasive bladder cancer who are ineligible for or have refused cisplatin-based chemotherapy.
Not affiliated with or endorsed by the FDA. pdufa.bio is an independent publication with no affiliation with, endorsement by, sponsorship by, or connection to the U.S. Food and Drug Administration or any other government agency. “FDA”, “PDUFA” and all company, drug and ticker names are used descriptively and remain the property of their respective owners.
Informational and educational purposes only. Not investment advice. Nothing on this page is investment, legal, tax or medical advice, or an offer or solicitation to buy or sell any security. pdufa.bio is not a registered investment adviser or broker-dealer and does not recommend trades or publish individual-drug approval probabilities. Verify every date and outcome against primary FDA, SEC or company filings. Data is provided as is, without warranty of any kind, and past behaviour does not predict future outcomes.